Born as Microbia over twenty years ago, Ironwood Pharmaceuticals(IRWD) trades just 21% above its 2010 IPO price. It has managed to get to market with LINZESS, a treatment for IBS. Partnered with Allergan(AGN), LINZESS did $761.2 million in 2018 US sales. Now, Ironwood will be spinning off much of its R&D business as Cyclerion. Current Ironwood CEO and… Read More »
Way back in 2013, Pfizer (PFE) CEO Ian Read plotted a future course that could have included a spinoff several years down the line. Since then there have been constant rumors and speculations about possible breakups and portfolio changes, but those were ultimately rejected. Last week though, the company shifted gears by formally announcing that it is considering its… Read More »
BioGen (BIIB) has finally chosen a name for its upcoming hemophilia drug focused spinoff. The new company will be called Bioverativ and it will eventually trade on the Nasdaq under the ticker ‘BIVV’. Bioverativ will be a global biotech company ‘focused on the discovery, research, development and commercialization of treatments for hemophilia and other blood disorders.’ It’s growing… Read More »